Elicio Therapeutics, Inc. (ELTX)
1.50
-0.09
(-5.66%)
USD |
NASDAQ |
Nov 19, 16:00
1.485
-0.02
(-1.00%)
Pre-Market: 20:00
Elicio Therapeutics Shareholders Equity (Quarterly) : 18.85M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 18.85M |
| June 30, 2026 | 7.937M |
| March 31, 2026 | -1.437M |
| December 31, 2025 | 1.636M |
| September 30, 2025 | 3.816M |
| June 30, 2025 | 1.834M |
| March 31, 2025 | 8.904M |
| December 31, 2024 | -11.31M |
| September 30, 2024 | -18.99M |
| June 30, 2024 | -1.652M |
| March 31, 2024 | 4.87M |
| December 31, 2023 | 11.37M |
| September 30, 2023 | 13.29M |
| June 30, 2023 | 23.56M |
| Date | Value |
|---|---|
| March 31, 2023 | 39.67M |
| December 31, 2022 | 8.915M |
| September 30, 2022 | 50.21M |
| June 30, 2022 | |
| March 31, 2022 | 67.20M |
| December 31, 2021 | 81.51M |
| September 30, 2021 | 64.51M |
| June 30, 2021 | 77.19M |
| March 31, 2021 | 92.44M |
| December 31, 2020 | -90.45M |
| September 30, 2020 | -63.19M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -18.59M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | 67.06M |
| Armata Pharmaceuticals, Inc. | -174.13M |
| Voyager Therapeutics, Inc. | 135.11M |
| Black Diamond Therapeutics, Inc. | 88.08M |
| Invivyd, Inc. | 150.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 39.60M |
| Total Liabilities (Quarterly) | 20.74M |
| Debt to Equity Ratio | 0.7422 |
| Current Ratio | 3.428 |
| Net Debt Paydown Yield | 0.35% |